logo
Why Many Millionaires Choose to Rent, Not Buy

Why Many Millionaires Choose to Rent, Not Buy

Epoch Times15-05-2025

Home ownership is the classic American dream. Traditionally, owning a home has been a mark of success and financial security.
That dream is changing for many millionaires, with many affluent individuals opting out of high-priced homes for their primary residences and instead choosing luxury rentals.
Why would high-net-worth individuals rent? It's all about price, investing, and lifestyle.
Living in Luxury, Waiting for Rates to Settle
According to Freddie Mac, in May 2025, the average 30-year mortgage interest rate is 6.76 percent. That's down from May 2024's 7.22 percent, but still higher than pre-pandemic rates.
A historical analysis of mortgage rates from Rocket Mortgage shows 2019 interest rates at 3.94 percent, dipping further in 2021 to 2.96 percent.
With higher interest rates come higher monthly payments. And luxury homes aren't immune.
The monthly payment for new homes increased by 11 percent year over year in May. By way of contrast, an analysis from apartment listing marketplace
Related Stories
5/3/2025
4/16/2025
Although many affluent individuals can afford higher home prices, they are choosing not to buy. Instead, they're turning to luxury home rentals, which can provide premium lifestyle choices until interest rates stabilize.
Thinking About Wealth Differently
There's a shift in how millionaires are looking at their wealth and how they will spend it. Instead of tying up large sums of money in a primary residence, many millionaires are choosing to diversify their portfolios by investing in real estate.
Buying property as an investment, rather than as a primary residence, has become a preferred method of capitalizing on the real estate market.
Many high-net-worth individuals consider home ownership a slower way to build wealth. Instead of buying a home to live in, they're opting to diversify their portfolios by investing in commercial properties and purchasing multiple properties in different markets.
Investing in real estate tends to provide a stable cash flow and benefits from the appreciation of assets.
The stock market is another area in which former homeowners are investing their funds. It allows them to see a higher and faster return than they would if they owned a home and waited for its value to appreciate.
For example, the S&P 500 has delivered a mean annual return of 9.4 percent over the past 25 years. But in 2023, it delivered a 26.29 percent return, and in 2024, a 25.02 percent return. A primary residence generally would not have generated that kind of return.
Purchasing a home requires upfront costs. You must pay down payments and closing fees. You'll also have maintenance costs and taxes. Taking those funds and investing them instead is a better option for many people.
Luxury Living, Low Maintenance
Luxury rentals are attractive to many affluent people because they offer more than just a place to live.
They provide a lifestyle that many wouldn't have otherwise: fitness centers, concierge services, and resort-style amenities.
Renting provides the flexibility to relocate for career or leisure opportunities without having to sell a home.
Add to that an extra 42 days to close, according to
Those numbers make a rental look much more attractive if you think you may relocate.
In addition, many affluent people travel or have more than one home. Another benefit of a rental such as a luxury condo is that the tenant doesn't have to worry about home maintenance while they're traveling.
Developers Respond
Developers have responded to the demand for luxury apartments with enthusiasm. With land at a premium in most cities, many developers are building luxury units where higher rent can be charged.
This may backfire, however. Even though many affluent individuals are moving toward renting, there is a limited number of these high-net-worth tenants.
According to the
Although the United States faces a housing shortage overall, developers have tried to capitalize on the luxury apartment trend, flooding the market with well-appointed apartments for what is actually a small group of people.
For example, according to a
Mr. Blandings Rents His Dream House
For many affluent individuals, owning a home is not a financial move they want to make.
Instead, they're shifting dollars to investments. The thinking is that investing wisely can bring in higher returns than waiting for a purchased home to appreciate.
There are other reasons as well: Some people want the luxury apartment experience that many of these units afford, while others are looking for the flexibility that only renting can provide.
The Epoch Times copyright © 2025.
The views and opinions expressed are those of the authors. They are meant for general informational purposes only and should not be construed or interpreted as a recommendation or solicitation. The Epoch Times does not provide investment, tax, legal, financial planning, estate planning, or any other personal finance advice. The Epoch Times holds no liability for the accuracy or timeliness of the information provided.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Health care stocks are due for a turnaround after a historically bad month, according to the charts
Health care stocks are due for a turnaround after a historically bad month, according to the charts

CNBC

time23 minutes ago

  • CNBC

Health care stocks are due for a turnaround after a historically bad month, according to the charts

The Health Care Select Sector SPDR Fund (XLV) was down over 5% in May, as the S & P 500 gained over 6%, which means that XLV underperformed the index by 11%. That's a huge performance discrepancy. In fact, it was the worst relative monthly percent move vs. the SPX in XLV's history, dating back to late 1998. As is clear from this long-term chart, the odds of this horribly bad relative weakness continuing at this same pace is low – at least for June. XLV itself now has approached two major long-term support levels after the recent downturn. The first is the rising trendline that begins at the 2009 financial crisis low and extends through the Covid bottom. XLV tested this line in mid-May, bounced and finished the month modestly off its lows. The second key support zone comes from the cluster of lows in 2021, 2022 and 2023, noted by the horizontal line that's in the low 120s. The converging lines present a confluence of support that clearly could help XLV's bouncing prospects in June. XLV: The 3 biggest holdings Believe it or not, 34 of XLV's 61 components actually logged gains in May. That's encouraging, but we'll need to see its biggest holdings respond soon. If they can't rally, XLV will continue to struggle. The three largest stocks within the ETF are Eli Lilly , Johnson & Johnson and AbbVie , which make up nearly 27% of XLV combined. So, what are the odds that all three stocks actually can mount strong up-moves in June? Let's take a closer look. We'll start with LLY since it's XLV's biggest component, with a 12% weighting. LLY last made an all-time high in August 2024. From that peak to its April low, the stock lost 30%. But as the following weekly chart (in log scale) shows, it wasn't straight down from there. LLY logged various rallies and drawdowns since then, all of which have taken place within the pictured downward sloping trading channel. The best time to buy LLY, thus, has been after a big, long decline. The stock just fell another 20% from April 30 through May 25. As we can see, the past ensuing bounces yielded big percentage moves, even if they ultimately failed to break through the channel's upper threshold. Additionally, LLY's weekly Williams %R indicator (on the lower panel) is emerging from an oversold condition, which has supported three of the last four big up-moves. In fact, LLY quietly has logged gains in six of the last seven trading days. That's a good start. JNJ (7.7% weight) has been trending lower since topping in 2022, while ABBV (6.8%) has been in a clear uptrend the last few years. However, both have experienced various swings within their respective long-term trading channels — like LLY. And with both JNJ and ABBV having sold off from their 2025 highs, now would be an opportune time for the next bounce to commence. From a big picture market perspective, rotation is an important component of true, long-lasting uptrends. Thus, if/when the air comes out of the more extended sectors and groups soon, capital could find its way to the underperforming areas, which of course, includes health care. DISCLOSURES: None. All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, NBC UNIVERSAL, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THE ABOVE CONTENT IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY . THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL'S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer.

Corteva (NYSE:CTVA) Partners With FMC To Expand Fluindapyr Fungicide In U.S. Markets
Corteva (NYSE:CTVA) Partners With FMC To Expand Fluindapyr Fungicide In U.S. Markets

Yahoo

time23 minutes ago

  • Yahoo

Corteva (NYSE:CTVA) Partners With FMC To Expand Fluindapyr Fungicide In U.S. Markets

Corteva recently entered a partnership with FMC Corporation to expand the use of FMC's fluindapyr fungicide technology in key markets, potentially enhancing its competitive edge. Over the last quarter, Corteva's stock saw a 16% increase, influenced by strong Q1 earnings and the approval of a cash dividend. The company also maintained its earnings guidance, suggesting stability and resilience, alongside its ongoing share repurchase program. These factors likely added weight to the stock's performance, aligning with the general upward market trend of 13% over the past year. Be aware that Corteva is showing 1 risk in our investment analysis. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. The recent partnership between Corteva and FMC Corporation to expand fluindapyr fungicide technology usage could bolster Corteva's competitive standing by enhancing its product offerings. This development aligns with Corteva's ongoing efforts to grow its market share, particularly in key regions like Brazil. Such initiatives contribute to anticipated revenue growth driven by strong demand for advanced seed technologies. Despite potential currency and pricing pressures, the company's strategic focus on cost initiatives and productivity enhancements may support improved earnings outcomes. Analysts project steady growth, with revenue expected to rise 2.9% annually over three years, and a potential increase in profit margins. These forecasts may reflect the positive effect of this collaboration on Corteva's financial future. Over the past five years, Corteva's total shareholder return, inclusive of share price movements and dividends, reached 155.14%. In contrast, a one-year comparison shows Corteva outperforming the US market return of 11.9% and significantly exceeding the US Chemicals industry's negative return. This longer-term performance showcases Corteva's resilience and investor appeal, although current share price movements indicate a 0.019% discount to the consensus price target of $72.56. As revenue and earnings forecasts factor in potential partnership gains, Corteva's share price trajectory could more closely align with analyst expectations. The consensus target suggests a 9.7% upside from the current price of $62.45, and the company's commitment to share repurchases and improving operating free cash flow further supports potential future returns. Gain insights into Corteva's past trends and performance with our report on the company's historical track record. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:CTVA. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store